血清和糖皮质激素调节激酶1在中枢神经系统疾病中的作用机制及其药物干预研究现状  

SGK1 as a therapeutic target for central nervous system diseases

作　　者：邢亚康 罗维 范梦瑶 谭雅薇 黎晓[1] XING Ya-Kang;LUO Wei;FAN Meng-Yao;TAN Ya-Wei;LI Xiao(College of Basic Medical Sciences,Gannan Medical University,Ganzhou 341000,China)

机构地区：[1]赣南医学院基础医学院,赣州341000

出　　处：《生理学报》2023年第3期451-464,共14页Acta Physiologica Sinica

基　　金：supported by the National Natural Science Foundation of China(No.82160688,31760290);Key Development Areas Project of Ganzhou Science and Technology(No.2022B-SF9554);the Innovation Team Foundation of Gannan Medical University(No.TD2021JC06)。

摘　　要：血清和糖皮质激素调节激酶1(serum and glucocorticoid-regulated kinase 1,SGK1)在神经系统激素释放、神经元兴奋和细胞增殖等生理过程中均发挥重要作用,SGK1也参与了中枢神经系统炎症及细胞凋亡等病理生理过程。越来越多的证据表明,SGK1可能作为干预神经退行性疾病的关键性靶点。本文就SGK1在中枢神经系统功能调控中的作用及其分子机制的研究进展作一综述,并对最新发现的以SGK1为干预靶点的药物在中枢神经系统疾病中的潜力进行了讨论。Serum and glucocorticoid-regulated kinase 1(SGK1)plays an important role in the physiological processes of hormone release,neuronal excitation and cell proliferation.SGK1 also participates in the pathophysiological processes of inflammation and apoptosis in the central nervous system(CNS).Increasing evidence demonstrates that SGK1 may serve as a target of the intervention of neurodegenerative diseases.In this article,we summarize the recent progress on the role and molecular mechanisms of SGK1 in the regulation of the function of the CNS.We also discuss the potential of newly discovered SGK1 inhibitors in the treatment of CNS diseases.

关 键 词：血清和糖皮质激素调节激酶1 脑缺血 创伤后应激障碍 分子抑制剂 

分 类 号：R741[医药卫生—神经病学与精神病学]